A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

A nutritionist has said it's 'extremely worrying' that so many people are deficient in a mineral that can be easily obtained ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...